98%
921
2 minutes
20
Rationale: The association between CFTR genotype, sweat chloride and mortality has been inconsistent, but no previous analyses have examined the association stratified by individual genotypes.
Objectives: To evaluate the genotype-specific association between sweat chloride and mortality.
Methods: The CFF Patient Registry was assessed and included all patients in the registry between 1996 and 2012 with at least one F508del allele. We excluded patients without a documented genotype or plausible sweat chloride level. The primary outcome was time to mortality during the observation period. We examined 15 genotypes using the three most prevalent alleles in each of 5 classes. We compared subgroups of sweat chloride using Kaplan-Meier curves, log-rank tests, and multivariable Cox PH models. The overall predictive value of sweat chloride on mortality was assessed using area under the receiver operating characteristic curves.
Measurements And Main Results: 18,893 subjects met inclusion criteria. Sweat chloride distribution was similar across genotypes in patients with class 1 mutations, but was significantly different across genotypes in mutation classes 2-5. The R117H/F508del genotype patients demonstrated an association between sweat chloride and mortality (HR: 1.32 for every 10mmol/L increase in sweat chloride [95% CI 1.12-1.54]. There were also significant associations in patients with F508del/F508del, I507del/F508del, G551D/F508del and 2789+5G→A/F508del genotypes, though the clinical relevance for these genotypes is unclear.
Conclusions: There is significant variability in sweat chloride distribution across CFTR class 2-5 genotypes. The relationship between sweat chloride and mortality varies by genotype with a relatively strong relationship in R117H/F508del patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcf.2017.11.002 | DOI Listing |
Lancet Respir Med
September 2025
Department for Paediatric Pneumology, Allergology, and Neonatology and German Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease, Hannover Medical School, 30625 Hannover, Germany. Electronic address:
Lancet Respir Med
September 2025
Effi-Stat, Paris, France.
Background: Among people with cystic fibrosis, sweat chloride and lung function response to elexacaftor-tezacaftor-ivacaftor (ETI) is variable. We hypothesised that the presence of two versus one ETI-responsive CFTR variant could predict response variability.
Methods: In this analysis of two real-world observational studies, data from a French national cohort of adults (aged ≥18 years) with cystic fibrosis and at least one F508del variant treated with ETI and the French compassionate programme for ETI in people (aged ≥6 years) with cystic fibrosis without F508del were used to examine sweat chloride concentrations (SCCs) after ETI initiation, and the absolute change in SCC and percentage of predicted forced expiratory volume in 1 s (ppFEV) following ETI initiation.
J Cyst Fibros
August 2025
Department of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium; Department of Pediatrics, Pediatric Pulmonology, University Hospital Leuven, Leuven, Belgium.
Background: Patient-derived intestinal organoids (PDIOs) are an in vitro tool used to predict clinical responses to CFTR modulators in people with cystic fibrosis (pwCF). Although strong genotype-based correlations have been observed, individual responses among F508del homozygous pwCF remain variable. We aimed to assess this correlation specifically within this group.
View Article and Find Full Text PDFNeurochem Int
August 2025
Department of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, China; Department of Thoracic Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China. Electronic ad
Background: Primary focal hyperhidrosis (PFH) is characterized by excessive sweating in localized regions, significantly impacting patients' quality of life. The imbalance between sodium-potassium-chloride cotransporter 1 (NKCC1) and potassium-chloride cotransporter 2 (KCC2) disrupts chloride ion homeostasis, potentially contributing to the pathogenesis of PFH.
Methods: Sweat gland tissues from 76 healthy controls and 76 PFH patients were collected.
Int J Neonatal Screen
July 2025
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98105, USA.
An unintended consequence of cystic fibrosis (CF) newborn screening (NBS) is the identification of infants with a positive NBS who do not meet the diagnostic criteria for CF (two CF-causing variants and/or sweat chloride > 60 mmol/L). This indeterminate diagnosis is called cystic fibrosis transmembrane conductance regulator (CFTR)-related metabolic syndrome (CRMS) or CF screen positive, inconclusive diagnosis (CFSPID). CRMS/CFSPID occurs when it is not clearly known whether variants are disease-causing.
View Article and Find Full Text PDF